Yang Huanzhang, Hua Jingli, Han Yanxia, Chang Dong, Zheng Wenlong
Department of Clinical Laboratory, Shanghai Pudong Hospital, Fudan University Pudong Medical Center, Shanghai, China.
Sci Rep. 2025 Jan 2;15(1):528. doi: 10.1038/s41598-024-84128-2.
Our aim was to investigate the potential value of immune-related miRNA signaling in predicting clinical prognosis and immunotherapy. We first identified immune-related miRNAs in lung adenocarcinoma (LUAD), and then constructed a miRNA-based risk model by lasso regression modeling. Finally, we validated our findings using RT-qPCR in serum from LUAD patients and normal patients. Weighted gene co-expression network analysis (WGCNA) was used to screen the aberrantly expressed genes associated with immune scores, and then correlation analysis and prognostic analysis were used to identify and immune-associated miRNAs, and lasso-cox regression was used to construct an immune-associated 5-miRNA model. Risk score as an independent prognostic factor could accurately predict the prognosis of LUAD patients. Immunotherapy analysis revealed that patients with low-risk scores benefited more from anti-PD-1 and CTLA-4 therapy. Experimental validation showed that only miRNA-200b-3p was significantly differentially expressed in 91 cases of clinically collected cancer tissues and normal tissue serum. We constructed a 5-miRNA model that can be used for risk stratification of LUAD patients. Targeted therapy against miRNA-200b-3p is expected to be a prospective new strategy for the clinical treatment of LUAD.
我们的目的是研究免疫相关miRNA信号在预测临床预后和免疫治疗方面的潜在价值。我们首先在肺腺癌（LUAD）中鉴定出免疫相关miRNA，然后通过套索回归建模构建基于miRNA的风险模型。最后，我们使用RT-qPCR在LUAD患者和正常患者的血清中验证了我们的发现。加权基因共表达网络分析（WGCNA）用于筛选与免疫评分相关的异常表达基因，然后通过相关性分析和预后分析来鉴定免疫相关miRNA，并使用套索-考克斯回归构建免疫相关的5-miRNA模型。风险评分作为独立的预后因素可以准确预测LUAD患者的预后。免疫治疗分析显示，低风险评分的患者从抗PD-1和CTLA-4治疗中获益更多。实验验证表明，在91例临床收集的癌组织和正常组织血清中，只有miRNA-200b-3p有显著差异表达。我们构建了一个可用于LUAD患者风险分层的5-miRNA模型。针对miRNA-200b-3p的靶向治疗有望成为LUAD临床治疗的一种前瞻性新策略。
